Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25697
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Khumra, Sharmila | - |
dc.contributor.author | Mahony, Andrew A | - |
dc.contributor.author | Bergen, Phillip J | - |
dc.contributor.author | Elliott, Rohan A | - |
dc.date | 2021-01-15 | - |
dc.date.accessioned | 2021-01-26T22:55:57Z | - |
dc.date.available | 2021-01-26T22:55:57Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.citation | British Journal of Clinical Pharmacology 2021; 87(8): 3354-3358 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/25697 | - |
dc.description.abstract | Timely intravenous (IV) to oral antimicrobial switch (IV-oral-switch) is a key antimicrobial stewardship (AMS) strategy. We aimed to explore concordance with IV-oral-switch guidelines in the context of a long-standing, tightly regulated AMS program. Data was retrospectively collected for 107 adult general medical and surgical patients in an Australian hospital. Median duration of IV antimicrobial courses before switching to oral therapy was 3 days (interquartile range [IQR] 2.25-5.00). Timely IV-oral-switch occurred in 57% (n = 61) of patients. The median delay to switching was 0 days (IQR 0 to 1.25). In most courses (92/106, 86.8%), the choice of oral alternative after switching was appropriate. In 45% (47/105) of courses, total duration of therapy (IV plus oral) exceeded the recommended duration by >1.0 day. Excessive IV antimicrobial duration was uncommon at a hospital with a tightly regulated AMS program. Total duration of therapy was identified as an AMS target for improvement. | en |
dc.language.iso | eng | - |
dc.subject | antimicrobial stewardship | en |
dc.subject | antimicrobials | en |
dc.subject | guidelines | en |
dc.subject | hospital | en |
dc.subject | preauthoriziation | en |
dc.subject | switch therapy | en |
dc.title | Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | British Journal of Clinical Pharmacology | en |
dc.identifier.affiliation | Department of Medicine, Melbourne University, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Pharmacy | en |
dc.identifier.affiliation | Infectious Diseases | en |
dc.identifier.affiliation | Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Microbiology, Monash University, Melbourne, Victoria, Australia | en |
dc.identifier.doi | 10.1111/bcp.14734 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-3499-8652 | en |
dc.identifier.orcid | 0000-0002-7750-9724 | en |
dc.identifier.pubmedid | 33450086 | - |
local.name.researcher | Elliott, Rohan A | |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | Infectious Diseases | - |
crisitem.author.dept | Pharmacy | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.